Program
KRAS G12D Inhibitor INCB161734
Its studies are mostly in Hepatic Insufficiency · Pancreatic Neoplasms · Renal Insufficiency · Colorectal Neoplasms, led by Incyte.
Furthest: phase 3, since Apr 3, 20265 company-led studies, 4 open or runningNext primary completion: Jan 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 54 open or running | phase 3since Apr 3, 2026 | Dec 12, 2023 | Jan 1, 2027phase 1 · NCT06179160 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06179160 · 710 planned · United States, Australia, Belgium and more
- Apr 3, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07522073 · 588 planned · United States, Australia, Austria and more
- Sep 4, 20263 phase 1 studiesNCT07814404, NCT07853040, NCT07854249
Ahead
- Jan 1, 2027Primary completion: phase 1 study in Colorectal NeoplasmsNCT06179160
- Mar 30, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07854249
- Mar 31, 2027Primary completion: phase 1 study in Hepatic InsufficiencyNCT07853040
- Sep 15, 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07522073
TargetBeta
KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07854249Renal Insufficiency | 1 | Not yet recruiting | Mar 30, 2027 | 24 |
| NCT07853040Hepatic Insufficiency · United States | 1 | Recruiting | Mar 31, 2027 | 24 |
| NCT07814404Healthy Participants · United States | 1 | Completed | Oct 15, 2026 | 10 |
| NCT07522073Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Sep 15, 2028 | 588 |
| NCT06179160Colorectal Neoplasms · United States, Australia, Belgium and more | 1 | Recruiting | Jan 1, 2027 | 710 |
How it is read
Names in the registry
- “INCB161734”, 5 entries
Conditions, from the studies’ own filings
- Hepatic Insufficiency, 1 study
- Pancreatic Neoplasms, 1 study
- Renal Insufficiency, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.